Article Text

Download PDFPDF

5PSQ-083 Maribavir-induced toxic epidermal necrolysis in a liver transplant patient: a case report
  1. C Guzmán Cordero1,
  2. C Guijarro Sánchez2,
  3. B Aparicio Castellano1,
  4. L García Martínez1
  1. 1Hospital Universitario Reina Sofía, Pharmacy Service, Córdoba, Spain
  2. 2Hospital Universitario Reina Sofía, Dermatology Service, Córdoba, Spain


Background and Importance Cytomegalovirus (CMV) infection poses a significant threat to transplant recipients,1 often necessitating antiviral treatment. Ganciclovir and valganciclovir have been mainstays, but CMV resistance in over 20% of cases requires alternatives like foscarnet or cidofovir.2 Maribavir, a novel CMV UL97 protein kinase inhibitor, has emerged as an effective option.3 Here, we unveil a previously unreported adverse effect (AE) associated with maribavir.

Aim and Objectives Our aim is to report a case of toxic epidermal necrolysis (TEN) linked to maribavir intake.

Material and Methods In March 2021, a male liver-transplanted patient with CMV-related retinal necrosis developed severe pancytopenia during valganciclovir treatment, subsequently receiving foscarnet in multiple hospitalisations. In May 2023, maribavir was initiated, marking the first such case in our hospital. Within a month, the patient was readmitted with painful skin lesions and mucositis in oral and genital mucosa. TEN diagnose was assumed, evidenced by tense bullae, extensive epidermal detachment (60% of Body Surface Area), and a clearly positive Nikolsky sign. He was transferred to the ICU 3 days later and treated with a 5-day-course of 125 mg intravenous methylprednisolone and 2g/kg immunoglobulin.

Results The patient’s overall status improved, with reduced lesions and epidermal detachment. After 10 days, only scarring remained. This AE was classified as probable causality due to maribavir, with a score of 6 on the Naranjo Scale.4 The Spanish System for Pharmacovigilance of Human Drugs was informed of this event by the Pharmacy Service.

Conclusion and Relevance TEN, a life-threatening drug-associated AE, must be considered when prescribing. While antibiotics cause 25% of TEN cases, antivirals rarely induce it.5 This AE is especially noteworthy since maribavir, marketed in November 2022, has limited exposure to patients in Spain. Early-phase pharmacovigilance is crucial for detecting unreported AEs. Establishing multidisciplinary teams comprising physicians and pharmacists is essential to ensure drug safety, mitigating severe AEs.

References and/or Acknowledgements 1. Razonable RR. Clin Transplant. 2019;33:e13512. DOI: 10.1111/ctr.13512

2. Chemaly RF, et al. Clin Infect Dis. 2019;68(8):1420–1426. DOI: 10.1093/cid/ciy696

3. Livtencity technical data sheet. EMA. 2022.

4. Naranjo CA, et al. Clin Pharmacol Ther. 1981;30:239245. DOI: 10.1038/clpt.1981.154

5. Lee EY, et al. JAMA Dermatol. 2023;4:384–392. DOI:10.1001/jamadermatol.2022.6378

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.